Abstract OT1-03-16: EMBRACA: A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer
Litton, JK, Blum, JL, Im, Y-H, Martin, M, Mina, L, Roché, H, Visco, F, Yang, X, Lokker, NA, Lounsbury, DL, Eiermann, W
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
Abstract OT1-03-17: ABRAZO: An international phase 2 (2-stage, 2-cohort) study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer
Turner, NC, Balmaña, J, Fasching, PA, Hurvitz, SA, Rugo, HS, Telli, ML, Visco, F, Wardley, AM, Yang, X, Lokker, NA, Lounsbury, DL, Robson, ME
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article